Ultragenyx Pharmaceutical Stock Extends A 9-Day Losing Streak To A 20% Loss
A biotech firm’s extended slide prompts a closer look at the numbers behind the momentum.
Ultragenyx Pharmaceutical Inc. focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. The stock has now moved lower for 9 consecutive trading days.
That decline represents a cumulative loss of 20.5% and has erased about $738 million from the company’s market value, which now stands at about $2.9 billion.
RARE Versus The S&P 500, Streak And Beyond
Here is how RARE stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | RARE | S&P 500 |
|---|---|---|
| 1D | -2.6% | -0.2% |
| 9D (Current Streak) | -20.5% | -0.8% |
| 1M (21D) | 6.0% | 0.3% |
| 3M (63D) | 15.0% | 4.5% |
| YTD 2026 | 24.0% | 8.7% |
| 2025 | -45.3% | 16.4% |
| 2024 | -12.0% | 23.3% |
| 2023 | 3.2% | 24.2% |
The selling reflects a conflict between growth and profitability.
The market may be weighing the company’s financial performance. While revenue over the last twelve months grew 13.5%, outpacing the S&P 500 median of 7.5%, its operating margin is -83.8%. This compares to an S&P 500 median of 18.4%. Ultragenyx also has negative trailing earnings.
This move is specific to the stock. Over the same 9 trading days, the S&P 500 returned -0.8%. For context, 42 S&P 500 stocks are currently on losing streaks of 3 days or more.
A streak is information, not an instruction.
An extended move in one direction is a clear signal of market attention and momentum. It is not, however, a simple directive to buy or sell.
The disciplined approach is to use the new information as a prompt to re-examine the business fundamentals against the stock’s current price. The data here provides a starting point for that assessment.
If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
Those watching the group rather than this one name have another route: a biotech ETF like XBI owns the whole group. That way no single company’s next surprise decides the outcome.
RARE Has Fallen 82% From A Peak Before
A stock that falls day after day is a live lesson in what single name exposure feels like. RARE itself has fallen 82% from a peak within the past five years, and a fall like that lands very differently when one position carries too much of your wealth. Knowing what a repeat would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.